Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia?

Powers RW, Roberts JM, Plymire DA, Pucci D, Datwyler SA, Laird DM, Sogin DC, Jeyabalan A, Hubel CA, Gandley RE.

Hypertension. 2012 Jul;60(1):239-46. doi: 10.1161/HYPERTENSIONAHA.112.191213. Epub 2012 May 29.

2.

Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor.

Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, Crombleholme WR, Ness RB, Roberts JM, Hubel CA.

J Clin Endocrinol Metab. 2005 Aug;90(8):4895-903. Epub 2005 May 10.

PMID:
15886253
3.

A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.

Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine RJ, Karumanchi SA.

J Matern Fetal Neonatal Med. 2008 Jan;21(1):9-23. doi: 10.1080/14767050701830480.

4.

First-Trimester Maternal Serum Levels of sFLT1, PGF and ADMA Predict Preeclampsia.

Bian Z, Shixia C, Duan T.

PLoS One. 2015 Apr 23;10(4):e0124684. doi: 10.1371/journal.pone.0124684. eCollection 2015.

5.

Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.

Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group.

N Engl J Med. 2006 Sep 7;355(10):992-1005. Erratum in: N Engl J Med. 2006 Oct 26;355(17):1840.

6.

Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison.

Andersen LB, Frederiksen-Møller B, Work Havelund K, Dechend R, Jørgensen JS, Jensen BL, Nielsen J, Lykkedegn S, Barington T, Christesen HT.

J Am Soc Hypertens. 2015 Feb;9(2):86-96. doi: 10.1016/j.jash.2014.11.008. Epub 2014 Dec 3.

PMID:
25600419
7.

Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.

Govender N, Naicker T, Rajakumar A, Moodley J.

Eur J Obstet Gynecol Reprod Biol. 2013 Sep;170(1):100-5. doi: 10.1016/j.ejogrb.2013.05.021. Epub 2013 Jun 24.

PMID:
23806447
8.

Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.

Leaños-Miranda A, Campos-Galicia I, Isordia-Salas I, Rivera-Leaños R, Romero-Arauz JF, Ayala-Méndez JA, Ulloa-Aguirre A.

J Hypertens. 2012 Nov;30(11):2173-81. doi: 10.1097/HJH.0b013e328357c0c9.

PMID:
22902831
9.

Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor.

Espinoza J, Romero R, Nien JK, Gomez R, Kusanovic JP, Gonçalves LF, Medina L, Edwin S, Hassan S, Carstens M, Gonzalez R.

Am J Obstet Gynecol. 2007 Apr;196(4):326.e1-13. Erratum in: Am J Obstet Gynecol. 2007 Jun;196(6):614.

10.

The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age.

Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, Gotsch F, Edwin S, Nien JK, Chaiworapongsa T, Mittal P, Mazaki-Tovi S, Than NG, Gomez R, Hassan SS.

J Matern Fetal Neonatal Med. 2008 May;21(5):279-87. doi: 10.1080/14767050802034545.

11.

Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study.

Rizos D, Eleftheriades M, Karampas G, Rizou M, Haliassos A, Hassiakos D, Vitoratos N.

Eur J Obstet Gynecol Reprod Biol. 2013 Dec;171(2):225-30. doi: 10.1016/j.ejogrb.2013.08.040. Epub 2013 Sep 4.

PMID:
24035323
12.

Human chorionic gonadotropin, angiogenic factors, and preeclampsia risk: a nested case-control study.

Asvold BO, Eskild A, Vatten LJ.

Acta Obstet Gynecol Scand. 2014 May;93(5):454-62. doi: 10.1111/aogs.12363.

PMID:
24575980
13.

Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia.

Wikström AK, Larsson A, Eriksson UJ, Nash P, Nordén-Lindeberg S, Olovsson M.

Obstet Gynecol. 2007 Jun;109(6):1368-74.

PMID:
17540809
14.

Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort.

Villa PM, Hämäläinen E, Mäki A, Räikkönen K, Pesonen AK, Taipale P, Kajantie E, Laivuori H.

BMC Pregnancy Childbirth. 2013 May 12;13:110. doi: 10.1186/1471-2393-13-110.

15.

Soluble Fms-like tyrosine kinase-1 to placental growth factor ratio in mid-pregnancy as a predictor of preterm preeclampsia in asymptomatic pregnant women.

Forest JC, Thériault S, Massé J, Bujold E, Giguère Y.

Clin Chem Lab Med. 2014 Aug;52(8):1169-78. doi: 10.1515/cclm-2013-0955.

PMID:
24535301
16.

Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.

Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ.

Circulation. 2010 Aug 3;122(5):478-87. doi: 10.1161/CIRCULATIONAHA.109.895458. Epub 2010 Jul 19. Erratum in: Circulation. 2011 Sep 13;124(11):e302.

17.

Placenta growth factor is not an early marker for the development of severe preeclampsia.

Livingston JC, Haddad B, Gorski LA, Neblett P, Ahokas RA, Ramsey R, Sibai BM.

Am J Obstet Gynecol. 2001 May;184(6):1218-20.

PMID:
11349191
18.

A longitudinal study of circulating angiogenic and antiangiogenic factors and AT1-AA levels in preeclampsia.

Sahay AS, Patil VV, Sundrani DP, Joshi AA, Wagh GN, Gupte SA, Joshi SR.

Hypertens Res. 2014 Aug;37(8):753-8. doi: 10.1038/hr.2014.71. Epub 2014 Apr 10.

PMID:
24718301
19.

Placental expression of VEGF family mRNA in adverse pregnancy outcomes.

Andraweera PH, Dekker GA, Laurence JA, Roberts CT.

Placenta. 2012 Jun;33(6):467-72. doi: 10.1016/j.placenta.2012.02.013. Epub 2012 Mar 3.

PMID:
22386962
20.

Circulating angiogenic factors in singleton vs multiple-gestation pregnancies.

Maynard SE, Moore Simas TA, Solitro MJ, Rajan A, Crawford S, Soderland P, Meyer BA.

Am J Obstet Gynecol. 2008 Feb;198(2):200.e1-7. doi: 10.1016/j.ajog.2007.08.042.

PMID:
18226624
Items per page

Supplemental Content

Write to the Help Desk